A Bni4-Glc7 Phosphatase Complex That Recruits Chitin Synthase to the Site of Bud Emergence

por Kozubowski, Lukasz, Panek, Heather, Rosenthal, Ashley, Bloecher, Andrew, DeMarini, Douglas J., Tatchell, Kelly
Publicado 2003

A Septin-based Hierarchy of Proteins Required for Localized Deposition of Chitin in the Saccharomyces cerevisiae Cell Wall

por DeMarini, Douglas J., Adams, Alison E.M., Fares, Hanna, Virgilio, Claudio De, Valle, Giorgio, Chuang, John S., Pringle, John R.
Publicado 1997

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies

por Forero-Torres, Andres, Ramchandren, Radhakrishnan, Yacoub, Abdulraheem, Wertheim, Michael S., Edenfield, William J., Caimi, Paolo, Gutierrez, Martin, Akard, Luke, Escobar, Carolina, Call, Justin, Persky, Daniel, Iyer, Swaminathan, DeMarini, Douglas J., Zhou, Li, Chen, Xuejun, Dawkins, Fitzroy, Phillips, Tycel J.
Publicado en Blood (2019)

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

por Kim, Kevin B., Kefford, Richard, Pavlick, Anna C., Infante, Jeffrey R., Ribas, Antoni, Sosman, Jeffrey A., Fecher, Leslie A., Millward, Michael, McArthur, Grant A., Hwu, Patrick, Gonzalez, Rene, Ott, Patrick A., Long, Georgina V., Gardner, Olivia S., Ouellet, Daniele, Xu, Yanmei, DeMarini, Douglas J., Le, Ngocdiep T., Patel, Kiran, Lewis, Karl D.
Publicado en J Clin Oncol (2013)

Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial

por Falchook, Gerald S, Lewis, Karl D, Infante, Jeffrey R, Gordon, Michael S, Vogelzang, Nicholas J, DeMarini, Douglas J, Sun, Peng, Moy, Christopher, Szabo, Stephen A., Roadcap, Lori T, Peddareddigari, Vijay G R, Lebowitz, Peter F, Le, Ngocdiep T, Burris, Howard A, Messersmith, Wells A, O'Dwyer, Peter J, Kim, Kevin B., Flaherty, Keith, Bendell, Johanna C., Gonzalez, Rene, Kurzrock, Razelle, Fecher, Leslie A
Publicado 2012

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma

por Villanueva, Jessie, Infante, Jeffrey R., Krepler, Clemens, Reyes-Uribe, Patricia, Samanta, Minu, Chen, Hsin-Yi, Li, Bin, Swoboda, Rolf K., Wilson, Melissa, Vultur, Adina, Fukunaba-Kalabis, Mizuho, Wubbenhorst, Bradley, Chen, Thomas Y., Liu, Qin, Sproesser, Katrin, DeMarini, Douglas J., Gilmer, Tona M., Martin, Anne-Marie, Marmorstein, Ronen, Schultz, David C., Speicher, David W., Karakousis, Giorgos C., Xu, Wei, Amaravadi, Ravi K., Xu, Xiaowe, Schuchter, Lynn M., Herlyn, Meenhard, Nathanson, Katherine L.
Publicado 2013